

#### SUMMARY

Data from patients with lung cancer and no/light smoking history from Greece are scarce. This retrospective study presents the clinicopathological and molecular characteristics of never/light smokers with LC from a tertiary hospital in Athens between 2010-2024. Multicentre and prospective studies are needed to better describe this subgroup of patients.

#### ΕΠΙΚΟΙΝΩΝΙΑ

Georgia Gomatou Second Propaedeutic Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece georgia.gomatou@gmail.com 2105832549 https://bpathologikiattikon.gr/

# Characteristics of lung cancer in never- and light-smokers: a retrospective, single-center study

Gomatou G.<sup>1</sup>, Kotsantis I.<sup>1</sup>, Kyriazoglou A.<sup>1</sup>, Anastasiou M.<sup>1</sup>, Pantazopoulos A.<sup>1</sup>, Foukas P.<sup>2</sup>, Gavrielatou N.<sup>1</sup>, Moutafi M.<sup>1</sup>, Boulouta A.<sup>1</sup>, Zazas E.<sup>1</sup>, Caglar C.<sup>1</sup>, Frantzi T.<sup>1</sup>, Gkaralea L.<sup>1</sup>, Kalfoutzou A.<sup>1</sup>, Psyrri A.<sup>1</sup>, Economopoulou P.<sup>1</sup> <sup>1</sup>Second Propaedeutic Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece <sup>2</sup>Second Department of Pathology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Lung cancer (LC) in never- and light-smokers accounts for 10-20% of all LC cases. Demographic, clinicopathologic and molecular data of LC patients with no/light smoking history from Greece are scarce.

in Greece.

This is a retrospective study enrolling all patients with LC from the Oncology Unit of a tertiary academic hospital in Athens between 2010-2024. Medical records were reviewed to identify never-smokers (<100 cigarettes during lifetime) and light-smokers Demographic, (<5 cigarettes/day). clinicopathologic and molecular data were recorded. Air quality index (AQI) was searched in https://www.iqair.com/.

# INTRODUCTION

### AIM

To describe LC in never- and light-smokers

### METHODS

We identified 67 cases of never- and light- smokers with LC in a total of 1280 LC patients (prevalence= 5.2% n=67/1280, neversmokers=39, light-smokers= 28, mean age±SD=69.1±12.0). Females constituted 64.1% (25/39) of never smokers. Professional exposure (silica dust and radon) was reported in 4.47% (3/67) of patients and 10.5% (7/67) had family history of at least one first-degree relative with LC. AQI of the patients' residence was moderate (51-100) in 53.7% and good (0-50) in 46.3% of the cases.

#### Variable

Demographics Age (mean  $\pm$  SD) Sex (female %) **Risk Factors** Professional exposure Family history AQI Moderate Good PD-L1 Negative (<1) Low (1-49) Hight (>50) **Oncogenic Alterations** EGFR del19/L858R EGFR exon 20 **RET** fusion ERRB2 amplification KRAS G12 mutations

## RESULTS

			alte
es	Ν	Results	wer
			(n=1
	67	69.1±12.0	amp
	67	34 (50.7%)	G12
			smo
	67	3 (4.47%)	Jinte
	67	7 (10.5%)	
	67	53.7 %	Our
	67	46.3 %	
			nat
	38	21	wit
	38	12	of
	38	5	pop
	46	21	
	46	11	
	46	1	
	46	1	1. L
	46	1	
	46	7	

Adenocarcinoma subtype was diagnosed in 83.5% of the patients; other subtypes included squamous (n=4), LCNEC (n=2), adenosquamous (n=1), NOS (n=1) and SCLC (n=1). PD-L1 expression (TPS) was available in 38 patients and was negative (<1%) in 21, low (1-49%) in 12 and high (>50%) in 5 patients. NGS was available in 15 patients and PCR testing of main driver genes in 31 patients. Oncogenic alterations were identified in 21 patients and re: EGFR exon 19 del/L858R point mutations :11), EGFR exon 20 insertion (n=1), ERBB2 plification (n=1), RET fusion (n=1) and KRAS 2 mutations (n=7, 6 light-smokers/1 neveroker). CONCLUSIONS data validate the need for multicenter tional registries of never- and light-smokers

#### RESULTS

th LC to identify the distinct characteristics this subgroup in different patient pulations.

## REFERENCES

\_oPiccolo J, Gusev A, Christiani DC, Jänne PA. Lung cancer in patients who have never smoked n emerging disease. Nat Rev Clin Oncol. 2024 Feb;21(2):121-146. doi: 10.1038/s41571-023-844-0. Epub 2024 Jan 9. PMID: 38195910; PMCID: PMC11014425.